Zevra Therapeutics (ZVRA) EPS (Weighted Average and Diluted) (2015 - 2026)
Zevra Therapeutics (ZVRA) reported EPS (Weighted Average and Diluted) of $0.6 for Q1 2026, up 1100.0% on a YoY basis from $0.05 in Q1 2025, and up 215.79% quarter-over-quarter from $0.19 in Q4 2025.
Zevra Therapeutics (ZVRA) EPS (Weighted Average and Diluted) (2015 - 2026) Analysis & Trends
Zevra Therapeutics has reported EPS (Weighted Average and Diluted) for 10 years, with the latest figure at $0.6 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 1100.0% year-over-year to $0.6; the trailing twelve-month figure through Mar 2026 stood at $1.99 (up 203.65% YoY), and the FY2025 full-year result was $1.35, up 159.21% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.6, up from $0.19 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $1.21 in Q2 2025, with the low at -$0.69 in Q3 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.01 across 3 years, with a median of -$0.04 in 2025.
- Annual changes were most pronounced in 2025 — EPS (Weighted Average and Diluted) jumped 98.55% — and 2026, when it soared 1100.0%.
- Zevra Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.69 in 2024, then soared by 127.54% to $0.19 in 2025, then surged by 215.79% to $0.6 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.6 (Q1 2026), $0.19 (Q4 2025), and -$0.01 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Zevra Therapeutics | 704.96 Mn | 504.34 Mn | 34.30 Mn | 0.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.60 |
| Dec 31, 2025 | 0.19 |
| Sep 30, 2025 | -0.01 |
| Jun 30, 2025 | 1.21 |
| Mar 31, 2025 | -0.06 |
| Dec 31, 2024 | -0.69 |
| Sep 30, 2024 | -0.69 |
| Jun 30, 2024 | -0.48 |
| Dec 31, 2021 | 0.05 |
| Sep 30, 2021 | -0.06 |
| Jun 30, 2021 | -0.40 |
| Mar 31, 2021 | -2.49 |
| Dec 31, 2020 | -1.13 |
| Sep 30, 2020 | -0.68 |
| Jun 30, 2020 | 0.21 |
| Mar 31, 2020 | -1.92 |
| Sep 30, 2019 | 0.06 |
| Jun 30, 2019 | -0.33 |
| Sep 30, 2018 | -0.94 |
| Jun 30, 2018 | -0.91 |